Subscribe
Magazine
Videos
Advertise
About Us
Smart Water Summit
Wastewater Summit
Drinking Water
Smart Water
Asset Management
Water Utility Management
Water Reuse
Global Thought Leaders
Podcast
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
WaterWorld Market Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Mirum Pharmaceuticals, Inc.
< Previous
1
2
3
4
5
Next >
Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences
November 18, 2022
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Tickers
MIRM
Mirum Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business Update
November 09, 2022
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Tickers
MIRM
Mirum Presents New Data from LIVMARLI Phase 3 PFIC Study and ALGS Infant Study in Late-Breaker Presentations at The Liver Meeting of AASLD
November 07, 2022
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Tickers
MIRM
Mirum Pharmaceuticals to Announce Third Quarter 2022 Financial Results and Host Conference Call on November 9, 2022
November 01, 2022
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Tickers
MIRM
Mirum’s LIVMARLI Data Featured in Two Late-Breaker Presentations at The Liver Meeting of the American Association for the Study of Liver Diseases
October 31, 2022
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Tickers
MIRM
Positive Topline Data Announced from Mirum’s LIVMARLI Phase 3 MARCH Study in Progressive Familial Intrahepatic Cholestasis (PFIC)
October 24, 2022
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Tickers
MIRM
Mirum Pharmaceuticals’ LIVMARLI Data Highlighting Quality of Life and Sleep Improvements in Patients with Alagille Syndrome Published in Journal of Pediatrics
October 18, 2022
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Tickers
MIRM
Mirum Pharmaceuticals Announces Positive CHMP Opinion for LIVMARLI® (maralixibat) Oral Solution for Cholestatic Pruritus in Patients with Alagille Syndrome Two Months of Age and Older
October 14, 2022
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Tickers
MIRM
Mirum Pharmaceuticals Presents Long-Term LIVMARLI® (maralixibat) Data and New Alagille Syndrome Caregiver Burden Analysis at NASPGHAN 2022 Annual Meeting
October 12, 2022
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Tickers
MIRM
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 10, 2022
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Tickers
MIRM
Mirum Pharmaceuticals to Present LIVMARLI® (maralixibat) Analyses and Host a Scientific Symposium at NASPGHAN 2022 Annual Meeting
October 05, 2022
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Tickers
MIRM
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 12, 2022
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Tickers
MIRM
Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences
August 30, 2022
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Tickers
MIRM
Mirum Pharmaceuticals Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares in Public Offering of Common Stock
August 12, 2022
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Tickers
MIRM
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 10, 2022
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Tickers
MIRM
Mirum Pharmaceuticals Announces Pricing of Public Offering of Common Stock
August 09, 2022
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Tickers
MIRM
Mirum Pharmaceuticals Announces Commencement of Public Offering of Common Stock
August 09, 2022
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Tickers
MIRM
Mirum Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Update
August 04, 2022
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Tickers
MIRM
Mirum Pharmaceuticals to Announce Second Quarter 2022 Financial Results and Host Conference Call on August 4, 2022
July 28, 2022
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Tickers
MIRM
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 08, 2022
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Tickers
MIRM
Mirum Pharmaceuticals Highlights Data Demonstrating Impact of LIVMARLI® (maralixibat) on Patients with Alagille Syndrome at European Society for Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN) Annual Meeting
June 24, 2022
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Tickers
MIRM
Mirum Pharmaceuticals Presents New Data at The International Liver Congress™ of the European Association for the Study of the Liver (EASL)
June 24, 2022
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Tickers
MIRM
Mirum Pharmaceuticals to Showcase LIVMARLI® (maralixibat) Data at EASL and ESPGHAN Annual Congresses
June 13, 2022
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Tickers
MIRM
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 10, 2022
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Tickers
MIRM
Mirum Pharmaceuticals Appoints Saira Ramasastry to Board of Directors
June 06, 2022
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Tickers
MIRM
Mirum Pharmaceuticals Acquires Satiogen Pharmaceuticals
May 23, 2022
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Tickers
MIRM
Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences
May 18, 2022
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Tickers
MIRM
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 10, 2022
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Tickers
MIRM
Mirum Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Business Update
May 05, 2022
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Tickers
MIRM
Mirum Pharmaceuticals to Announce First Quarter 2022 Financial Results and Host Conference Call on May 5, 2022
May 02, 2022
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Tickers
MIRM
< Previous
1
2
3
4
5
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.